Approval for new test format to be manufactured at matritech, inc., newton, massachusetts and at a new facility, unotech diagnostics, inc., san leandro, california.  The device, as modified, will be marketed under the trade name nmp22 bladderchek kit and is indicated for the following:  the matritech nmp22 bladderchek test is an in vitro immunoassay intended for the qualitative detection of nmp22 nuclear matrix protein in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer.  This test is indicated for professional use and prescription home use as an aid in diagnosing and monitoring bladder cancer patients, in conjunction with standard diagnostic procedures.